BBI.OQ
Latest Trade
1.17USDChange
0.01(+0.86%)Volume
363,738Today's Range
-
1.1852 Week Range
-
2.64As of on the NASDAQ ∙ Minimum 15 minute delay
Previous Close | 1.16 |
|---|---|
Open | 1.14 |
Volume | 363,738 |
3M AVG Volume | 81.59 |
Today's High | 1.18 |
Today's Low | 1.01 |
52 Week High | 2.64 |
52 Week Low | 0.47 |
Shares Out (MIL) | 53.52 |
Market Cap (MIL) | 62.61 |
Forward P/E | -1.65 |
Dividend (Yield %) | -- |
Brickell Biotech Inc - R. Michael Carruthers, CFO And Principal Accounting Officer, Will Be Resigning
Brickell Biotech Inc - Kaken Plans To Launch ECCLOCK For Treatment Of Primary Axillary Hyperhidrosis In Japan On November 26, 2020
Brickell Biotech Reports Q3 Revenue Of $100,000
Brickell Biotech, Inc., formerly Vical Incorporated, is a clinical-stage pharmaceutical company that focuses on the development of therapeutics for the treatment of skin diseases. The Company’s pipeline consists of molecular entities targeting the treatment of the indications, such as hyperhidrosis, cutaneous T-cell lymphoma, allergic contact dermatitis, psoriasis and androgenic alopecia. The Company’s product candidates include BBI-3000, BBI-6000 and Sofpironium Bromide. Sofpironium Bromide is a topical soft anticholinergic for axillary hyperhidrosis. BBI-3000 is an oral rexinoid for cutaneous T-cell lymphoma. BBI-6000 is a retinoic acid-related orphan nuclear receptor gamma antagonist, which is develops for psoriasis.
Industry
Biotechnology & Drugs
Contact Info
5777 Central Ave Ste 102
BOULDER, CO
80301-2870
United States
+1.720.5054755
https://brickellbio.com/Executive Leadership
Reginald L. Hardy
Chairman of the Board, Co-Founder
Robert B. Brown
Chief Executive Officer, Director
Andrew D. Sklawer
Co-Founder, Chief Operating Officer, Secretary
Albert N. Marchio
Chief Financial Officer
Jose Breton
Chief Accounting Officer, Controller
Price To Earnings (TTM) | -- |
|---|---|
Price To Sales (TTM) | 25.41 |
Price To Book (MRQ) | 1.95 |
Price To Cash Flow (TTM) | -- |
Total Debt To Equity (MRQ) | 2.34 |
LT Debt To Equity (MRQ) | 0.91 |
Return on Investment (TTM) | -113.66 |
Return on Equity (TTM) | -84.50 |
* BRICKELL BIOTECH ANNOUNCES POSITIVE PHASE 3 PIVOTAL STUDY RESULTS FOR SOFPIRONIUM BROMIDE IN JAPAN RELEASED BY DEVELOPMENT PARTNER, KAKEN PHARMACEUTICAL
* BRICKELL BIOTECH - OFFERING 15.2 MILLION SHARES OF COMMON STOCK & COMMON WARRANTS TO PURCHASE 7.6 MILLION SHARES OF CO'S COMMON STOCK Source text: (https://bit.ly/2ATpRpi) Further company coverage:
* BRICKELL BIOTECH REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
* BRICKELL BIOTECH INC FILES PROSPECTUS RELATES TO RESALE, FROM TIME TO TIME, OF UP TO 2.6 MILLION SHARES OF COMMON STOCK BY LINCOLN PARK CAPITAL FUND, LLC Source text: (https://bit.ly/3bAM0Gt) Further company coverage:
* BRICKELL BIOTECH INC - FILED AMENDMENT NO. 1 TO DEFINITIVE PROXY STATEMENT FILED BY CO ON MARCH 30
* BRICKELL BIOTECH - PROSPECTUS RELATES TO RESALE, FROM TIME TO TIME, OF UP TO 2.6 MILLION SHARES OF COMMON STOCK BY LINCOLN PARK CAPITAL FUND, LLC Source text: https://bit.ly/3aI2fkK Further company coverage:
* BRICKELL BIOTECH REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
* BRICKELL BIOTECH FILES PROSPECTUS RELATES TO OFFER, SALE FROM TIME TO TIME BY SELLING STOCKHOLDER OF UP TO 1.6 MILLION SHARES OF CO'S COMMON STOCK Source: (https://bit.ly/2PzRf0i) Further company coverage:
* LINCOLN PARK CAPITAL FUND LLC REPORTS 9.99% PASSIVE STAKE IN BRICKELL BIOTECH INC AS OF FEBRUARY 20, 2020 - SEC FILING Source text : (http://bit.ly/3a8REOV) Further company coverage:
* BRICKELL BIOTECH ANNOUNCES SETTLEMENT OF DISPUTE WITH BODOR LABS AND ENTRY INTO EQUITY FUNDING AGREEMENTS
* BRICKELL BIOTECH INC FILES FOR MIXED SHELF OF UP TO $75 MILLION – SEC FILING Source text: (https://bit.ly/38h14r9) Further company coverage:
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.